FDA said to order a review of St. jude (STJ) Riata Defibrillator leads
Tweet
Share
E-mailGet Alerts STJ Hot Sheet
Join SI Premium – FREE
St. Jude (NYSE: STJ) lower as the FDA is said to order a review of its Riata Defibrillator leads, according to the WSJ.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA maintains underperform ratings on six BDC stocks
- Barclays sees music streaming growth narrow gap with Spotify
- Wolfe Research sees CNH stock flat 2027 outlook on commodity prices
Create E-mail Alert Related Categories
FDA, General NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
